Outcomes of spinal fusion following autologous stem cell transplantation

Kashif A. Shaikh, Gregory M. Helbig, Eric Horn

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Patients who have undergone myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation (HSCT) for conditions such as multiple myeloma, Hodgkin's disease, and primary amyloidosis may be at higher risk for failure of spinal fusion. As HSCT care and outcomes continue to improve, it is increasingly likely that neurosurgeons will encounter patients post-HSCT who require spinal procedures. To our knowledge there are no published data on fusion outcomes in this unique patient population. We report three patients who underwent spinal fusion following an autologous HSCT. Spinal surgery was performed, on average, 4.5 years after autologous HSCT. No patients were on immunosuppressant chemotherapy at the time of the procedure, although one patient was being treated with rituximab for disease progression peri-operatively. Average radiographic confirmation of fusion was 37 months and all patients ultimately demonstrated fusion, although not without incident. Our results suggest that spinal fusion can occur in patients who have previously undergone myeloablative chemotherapy followed by autologous HSCT.

Original languageEnglish
Pages (from-to)62-65
Number of pages4
JournalJournal of Clinical Neuroscience
Volume20
Issue number1
DOIs
StatePublished - Jan 2013

Fingerprint

Spinal Fusion
Stem Cell Transplantation
Hematopoietic Stem Cell Transplantation
Drug Therapy
Immunosuppressive Agents
Multiple Myeloma
Hodgkin Disease
Disease Progression

Keywords

  • Bone marrow
  • Immunosuppression
  • Neurosurgical procedures
  • Spine
  • Stem cells
  • Transplantation

ASJC Scopus subject areas

  • Clinical Neurology
  • Neurology
  • Physiology (medical)

Cite this

Outcomes of spinal fusion following autologous stem cell transplantation. / Shaikh, Kashif A.; Helbig, Gregory M.; Horn, Eric.

In: Journal of Clinical Neuroscience, Vol. 20, No. 1, 01.2013, p. 62-65.

Research output: Contribution to journalArticle

Shaikh, Kashif A. ; Helbig, Gregory M. ; Horn, Eric. / Outcomes of spinal fusion following autologous stem cell transplantation. In: Journal of Clinical Neuroscience. 2013 ; Vol. 20, No. 1. pp. 62-65.
@article{a7fed44928cf4958bd9401b7e60ccba1,
title = "Outcomes of spinal fusion following autologous stem cell transplantation",
abstract = "Patients who have undergone myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation (HSCT) for conditions such as multiple myeloma, Hodgkin's disease, and primary amyloidosis may be at higher risk for failure of spinal fusion. As HSCT care and outcomes continue to improve, it is increasingly likely that neurosurgeons will encounter patients post-HSCT who require spinal procedures. To our knowledge there are no published data on fusion outcomes in this unique patient population. We report three patients who underwent spinal fusion following an autologous HSCT. Spinal surgery was performed, on average, 4.5 years after autologous HSCT. No patients were on immunosuppressant chemotherapy at the time of the procedure, although one patient was being treated with rituximab for disease progression peri-operatively. Average radiographic confirmation of fusion was 37 months and all patients ultimately demonstrated fusion, although not without incident. Our results suggest that spinal fusion can occur in patients who have previously undergone myeloablative chemotherapy followed by autologous HSCT.",
keywords = "Bone marrow, Immunosuppression, Neurosurgical procedures, Spine, Stem cells, Transplantation",
author = "Shaikh, {Kashif A.} and Helbig, {Gregory M.} and Eric Horn",
year = "2013",
month = "1",
doi = "10.1016/j.jocn.2012.05.009",
language = "English",
volume = "20",
pages = "62--65",
journal = "Journal of Clinical Neuroscience",
issn = "0967-5868",
publisher = "Churchill Livingstone",
number = "1",

}

TY - JOUR

T1 - Outcomes of spinal fusion following autologous stem cell transplantation

AU - Shaikh, Kashif A.

AU - Helbig, Gregory M.

AU - Horn, Eric

PY - 2013/1

Y1 - 2013/1

N2 - Patients who have undergone myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation (HSCT) for conditions such as multiple myeloma, Hodgkin's disease, and primary amyloidosis may be at higher risk for failure of spinal fusion. As HSCT care and outcomes continue to improve, it is increasingly likely that neurosurgeons will encounter patients post-HSCT who require spinal procedures. To our knowledge there are no published data on fusion outcomes in this unique patient population. We report three patients who underwent spinal fusion following an autologous HSCT. Spinal surgery was performed, on average, 4.5 years after autologous HSCT. No patients were on immunosuppressant chemotherapy at the time of the procedure, although one patient was being treated with rituximab for disease progression peri-operatively. Average radiographic confirmation of fusion was 37 months and all patients ultimately demonstrated fusion, although not without incident. Our results suggest that spinal fusion can occur in patients who have previously undergone myeloablative chemotherapy followed by autologous HSCT.

AB - Patients who have undergone myeloablative chemotherapy followed by autologous hematopoietic stem cell transplantation (HSCT) for conditions such as multiple myeloma, Hodgkin's disease, and primary amyloidosis may be at higher risk for failure of spinal fusion. As HSCT care and outcomes continue to improve, it is increasingly likely that neurosurgeons will encounter patients post-HSCT who require spinal procedures. To our knowledge there are no published data on fusion outcomes in this unique patient population. We report three patients who underwent spinal fusion following an autologous HSCT. Spinal surgery was performed, on average, 4.5 years after autologous HSCT. No patients were on immunosuppressant chemotherapy at the time of the procedure, although one patient was being treated with rituximab for disease progression peri-operatively. Average radiographic confirmation of fusion was 37 months and all patients ultimately demonstrated fusion, although not without incident. Our results suggest that spinal fusion can occur in patients who have previously undergone myeloablative chemotherapy followed by autologous HSCT.

KW - Bone marrow

KW - Immunosuppression

KW - Neurosurgical procedures

KW - Spine

KW - Stem cells

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=84871451158&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84871451158&partnerID=8YFLogxK

U2 - 10.1016/j.jocn.2012.05.009

DO - 10.1016/j.jocn.2012.05.009

M3 - Article

VL - 20

SP - 62

EP - 65

JO - Journal of Clinical Neuroscience

JF - Journal of Clinical Neuroscience

SN - 0967-5868

IS - 1

ER -